Dr. Michael Hemprich is a veterinarian by training. He graduated from Giessen Veterinary Faculty (Justus-Liebig-University) and obtained his PhD (Dr.med.vet) from Ludwig-Maximilian University in Munich. Over the last 26 years, Michael has held multiple global roles in the veterinary industry in Regulatory Affairs, R&D, and Business Development. He also has experience working in the human generic and innovative pharmaceutical industries. Amongst others, Michael has worked for Bremer Pharma, Intervet, LAB International in Canada (Veterinary and Human Pharma) and Dechra Pharmaceuticals in the UK. Following the acquisition of IDT's Animal Health business by Ceva Santé Animale in July 2019, he joined the Ceva Strategy and Business Development (SBD) Group in a Director role. Recently he joined Meiji Animal Health (MAH) as Senior Advisor to the President, supporting MAH to internationalise its Animal Health Business.